08.04.25 -- Meeting The Demand For Cell & Gene Therapy Commercialization

Mario Kraft, Director of Process Development at AGC Biologics' Heidelberg facility, explains how platform processes optimize microbial, plasmid DNA, and mRNA production.

Our team has decades of CGT development experience and can help you achieve maximum ROI with phase-appropriate designs, robust analysis, consistent product quality, and more.

Choose from our technology platforms or ask our scientists to customize a project. We’ll use our patented and proprietary technologies to ensure quality, accuracy, and fast turnaround times.

Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.

Introducing Aldevron’s latest innovation — Alchemy™ cell-free DNA technology. This enzymatic DNA manufacturing process produces linear DNA templates for in vitro transcription of mRNA.

Our proprietary AAVion® platform streamlines every step to accelerate your AAV program, from DoE process development to clinical and commercial GMP manufacturing.

The integrated technology platform is designed to accelerate patient access to prescribed cell and gene therapies and deliver complete visibility to physicians and patient services teams.

Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.

Our EpyQ™ AAV production system offers a novel two plasmid alternative to triple transfection— comparative studies can be run to see what benefits your process most.